Prio Wealth Limited Partnership’s Viridian Therapeutics VRDN Stock Holding History

Prio Wealth Limited Partnership’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-860	Closed	-$26K	–	261
2019 Q2	$26K	Hold	860	–	–	﹤0.01%	243
2019 Q1	$35K	Hold	860	–	–	﹤0.01%	239
2018 Q4	$39K	Hold	860	–	–	﹤0.01%	221
2018 Q3	$71K	Hold	860	–	–	﹤0.01%	240
2018 Q2	$82K	Hold	860	–	–	﹤0.01%	240
2018 Q1	$90K	Hold	860	–	–	﹤0.01%	240
2017 Q4	$134K	Hold	860	–	–	0.01%	232
2017 Q3	$117K	Buy	+860	New	+$145K	0.01%	234

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prio Wealth Limited Partnership's VRDN Position: Q3 2019 in Review

Prio Wealth Limited Partnership sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 860 shares — an estimated $26K sold.

Prio Wealth Limited Partnership first reported a position in VRDN in Q3 2017 and held it in 8 quarters. The position peaked at $134K in Q4 2017. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

Prio Wealth Limited Partnership reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
Prio Wealth Limited Partnership sold 860 Viridian Therapeutics shares in Q3 2019, an estimated $26K.
Prio Wealth Limited Partnership first reported a position in Viridian Therapeutics in Q3 2017 and held it in 8 quarters.
Prio Wealth Limited Partnership's Viridian Therapeutics position peaked at $134K in Q4 2017.
33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Prio Wealth Limited Partnership's 13F filing for Q3 2019, filed 13 Nov 2019.